# Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

Source: https://onco.cc/trials/nct00434148/  
OnCo record `nct00434148` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pasireotide in Pituitary tumours, run by Novartis Pharmaceuticals, completed.

## Summary

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease is a phase 3 interventional study registered as NCT00434148 by Novartis Pharmaceuticals, with 162 participants recorded, started 2006-12 and reaching its primary completion in 2010-03. Interventions recorded: Pasireotide. Conditions recorded: Cushing's Disease.

Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00434148
- Phase: 3
- Setting: A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT00434148: https://clinicaltrials.gov/study/NCT00434148

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Pasireotide](https://onco.cc/drugs/pasireotide/)

---
JSON: https://onco.cc/api/v1/entities/nct00434148.json